Aldevron and Odylia partner for gene therapy treatments of ultra-rare diseases. Odylia and Aldevron, a contract manufacturing organization specializing in the production of plasmid DNA and other biological agents, have entered into an agreement in which Aldevron is a member of Odylia. Under this agreement, Aldevron...
Odylia will be attending the International Symposium on Usher Syndrome July 19-21 in Mainz, Germany. CEO, Scott Dorfman, will be speaking during the scientific presentations on July 20 to present Odylia’s mission to move science to the clinic. Odylia will also present a poster at the...
Odylia will be attending the 2018 Annual Meeting of the American Society of Gene and Cell Therapy. We will be meeting with companies and individuals to discuss ways an Odylia partnership can quickly advance therapies for rare disease from the lab to the clinic. Visit Website...
Scott Dorfman, co-founder and CEO of Odylia, speaks to RARECast about what drove the creation of Odylia, how it works as a non-profit, and how we can extend our model to bring more therapies for rare disease to patients. Listen to Interview...
Massachusetts Eye and Ear says it has performed the first post-approval injection of the Luxturna®, which treats a form of blindness caused by RPE65 deficiency, otherwise known as RP20. The hospital announced on Tuesday that Jason Comander, the associate director of its inherited retinal disorders...
Odylia co-founders Scott Dorman and Luk Vandenberghe speak to Xconomy about the problems keeping gene therapies for rare disease from reaching patients. In this article, Dorfman and Vandenberghe speak about the dozens, if not hundreds, of inherited retinal dystrophies that could be amenable to treatment...
Odylia will be attending the second annual Gene Therapy for Rare Disorders conference in Boston. We will be speaking to companies and individuals about how Odylia can accelerate the development of gene therapies for rare disorders. Visit Website...
Odylia Therapeutics, a new nonprofit organization, will bring treatments to clinical trial for people at risk for blindness due to ultra-rare inherited retinal diseases. By leveraging our non-profit status and world-class expertise, we will bring forward therapies for indications which have been left behind by...